Isolagen Starts Phase III Program to Investigate Acne Treatment

November 9, 2007

Isolagen has begun a Phase III program for its treatment of moderate to severe acne scars.

Two randomized, double-blind, placebo-controlled trials will evaluate the safety and efficacy of Isolagen Therapy in patients with scarring on both sides of the face. All patients will receive active treatment on one side and placebo on the other.

The patients will receive three injections two weeks apart and be followed for four months after the final injection, Isolagen said.

The company also has a Phase III program to evaluate the Isolagen Therapy in treating wrinkles.